The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Pulse Biosciences, Inc. (NASDAQ: PLSE) securities between January 12, 2021 and February 7, 2022.
According to the Pulse lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the investigational device exemption study evaluating the use of the Company’s CellFX System to treat sebaceous hyperplasia lesions failed to meet its primary endpoints; (2) as a result, there was a substantial risk that the U.S. Food and Drug Administration would reject Pulse’s 510(k) submission seeking to expand the label for the CellFX System to treat sebaceous hyperplasia lesions; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Pulse you have until April 18, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.